DDInter781 DDInter1269
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Mitiglinide
Mitiglinide {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A2
SLC15A2 {u} (Gene) is bound by {v} (Compound) Nateglinide
Fosinopril {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Aspartame
Aspartame {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril {u} (Compound) resembles {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A2
SLC15A2 {u} (Gene) is bound by {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound)
Fosinopril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Fosinopril (Compound) resembles Mitiglinide (Compound) and Mitiglinide (Compound) resembles Nateglinide (Compound)
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fosinopril (Compound) binds SLC15A2 (Gene) and SLC15A2 (Gene) is bound by Nateglinide (Compound)
Fosinopril (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Fosinopril (Compound) resembles Trandolapril (Compound) and Trandolapril (Compound) resembles Nateglinide (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Aspartame (Compound) and Aspartame (Compound) resembles Nateglinide (Compound)
Fosinopril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound)
Fosinopril (Compound) binds SLC15A2 (Gene) and SLC15A2 (Gene) is bound by Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound)